These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 7804815)

  • 1. Inspections: the international regulatory view.
    Turner JL
    PDA J Pharm Sci Technol; 1994; 48(4):180-1. PubMed ID: 7804815
    [No Abstract]   [Full Text] [Related]  

  • 2. Inspections: the international regulatory view--Japan.
    Kamura S
    PDA J Pharm Sci Technol; 1994; 48(4):182-3. PubMed ID: 7804816
    [No Abstract]   [Full Text] [Related]  

  • 3. Counterfeiting and piracy of pharmaceuticals.
    Grackin A
    IEEE Eng Med Biol Mag; 2008; 27(6):66-9. PubMed ID: 19004698
    [No Abstract]   [Full Text] [Related]  

  • 4. Licensing under the Medicines Act and its effect on pharmacy.
    Fishburn AG
    R Soc Health J; 1974 Dec; 94(6):271-3, 95. PubMed ID: 4460083
    [No Abstract]   [Full Text] [Related]  

  • 5. WHO expert committee on specifications for pharmaceutical preparations.
    World Health Organization
    World Health Organ Tech Rep Ser; 2013; (981):i-xi, 1-188. PubMed ID: 23821930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global perspective on specifications for biotechnology products--perspective from Japan.
    Hayakawa T
    Dev Biol Stand; 1997; 91():15-23. PubMed ID: 9413678
    [No Abstract]   [Full Text] [Related]  

  • 7. The joint interagency task force and the global steering committee for the quality assurance of health products: two new and proactive approaches promoting access to safe and effective medicines.
    Cinnamond M; Woods T
    Am J Trop Med Hyg; 2015 Jun; 92(6 Suppl):133-136. PubMed ID: 26041869
    [No Abstract]   [Full Text] [Related]  

  • 8. The primacy of public health considerations in defining poor quality medicines.
    Newton PN; Amin AA; Bird C; Passmore P; Dukes G; Tomson G; Simons B; Bate R; Guerin PJ; White NJ
    PLoS Med; 2011 Dec; 8(12):e1001139. PubMed ID: 22162953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-second report.
    World Health Organ Tech Rep Ser; 1992; 823():1-134. PubMed ID: 1462605
    [No Abstract]   [Full Text] [Related]  

  • 10. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
    World Health Organization
    World Health Organ Tech Rep Ser; 2005; 929():1-142, backcover. PubMed ID: 16353684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory aspects of stability testing in Europe.
    Matthews BR
    Drug Dev Ind Pharm; 1999 Jul; 25(7):831-56. PubMed ID: 10459489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Guidelines for introducing new drugs for medical use in Poland and control of their quality].
    Danysz A
    Pol Tyg Lek; 1984 Dec 17-31; 39(51-52):1673-4. PubMed ID: 6522321
    [No Abstract]   [Full Text] [Related]  

  • 13. EC/FDA joint inspections.
    Nasto B
    Nat Biotechnol; 2008 Aug; 26(8):847. PubMed ID: 18688225
    [No Abstract]   [Full Text] [Related]  

  • 14. ISO 9000. Policy implications for FDA. Taking the pulse of increasing global use of the ISO series of uniform quality standards by FDA regulated industries.
    Schwemer WL; Lynch MA
    J Parenter Sci Technol; 1993; 47(3):101-18. PubMed ID: 8360802
    [No Abstract]   [Full Text] [Related]  

  • 15. Regulating Medicines in a Globalized World With Increased Recognition and Reliance Among Regulators: A National Academies Report.
    Gostin LO; Wood AJ; Cuff PA
    JAMA; 2020 Jul; 324(2):145-146. PubMed ID: 32134427
    [No Abstract]   [Full Text] [Related]  

  • 16. Mutual recognition agreements and harmonization.
    Horton L
    Seton Hall Law Rev; 1998; 29(2):692-735. PubMed ID: 10569828
    [No Abstract]   [Full Text] [Related]  

  • 17. The balance to be achieved between in-process controls and finished product testing.
    Hutton RC
    Boll Chim Farm; 1986 Jul; 125(7):221-7. PubMed ID: 3801165
    [No Abstract]   [Full Text] [Related]  

  • 18. Industry perspectives on ICH guidelines.
    Rockhold FW
    Stat Med; 2002 Oct; 21(19):2949-57. PubMed ID: 12325111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promoting public health and protecting consumers in a global economy: an overview of HHS/FDA's international activities.
    Kelly DP; Bachorik LL
    Food Drug Law J; 2005; 60(3):339-46. PubMed ID: 16304741
    [No Abstract]   [Full Text] [Related]  

  • 20. The importance and challenges of "mutual recognition".
    Merrill RA
    Seton Hall Law Rev; 1998; 29(2):736-55. PubMed ID: 10569829
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.